CD10+ fibroblasts are more involved in the progression of hilar/extrahepatic cholangiocarcinoma than of peripheral intrahepatic cholangiocarcinoma

Histopathology

Volumn 55, Issue 4, 2009, Pages 423-431

  Nishihara, Yunosuke ^a   Aishima, Shinichi ^a   Hayashi, Akifumi ^a   Iguchi, Tomohiro ^a   Fujita, Nobuhiro ^a   Taketomi, Akinobu ^b   Honda, Hiroshi ^a   Tsuneyoshi, Masazumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Department of Surgery and Sciences ^*

Author keywords

CD10 (neutral endopeptidase); Cholangiocarcinoma; Stromal interaction; Tumour progression

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CANCER LOCALIZATION; CANCER SURGERY; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FIBROBLAST; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER HILUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

AGED; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; DISEASE PROGRESSION; FEMALE; FIBROBLASTS; HUMANS; MALE; MIDDLE AGED; NEPRILYSIN; PROGNOSIS; SURVIVAL RATE;

EID: 70349934740     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03398.x     Document Type: Article

References (32)

1. Khan SA, Thomas HC, Davidson BR et al. Cholangiocarcinoma. Lancet 2005 366 1303 1314.
2. Anderson CD, Pinson CW, Berlin J et al. Diagnosis and treatment of cholangiocarcinoma. Oncologist 2004 9 43 57.
3. Chu P, Arber DA. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am. J. Clin. Pathol. 2000 113 374 382.
4. Borscheri N, Roessner A, Rocken C. Canalicular immunostaining of neprilysin (CD10) as a diagnostic marker for hepatocellular carcinomas. Am. J. Surg. Pathol. 2001 25 1297 1303.
5. Xiao SY, Wang HL, Hart J et al. cDNA arrays and immunohistochemistry identification of CD10/CALLA expression in hepatocellular carcinoma. Am. J. Pathol. 2001 159 1415 1421.
6. Morrison C, Marsh W, Frankel WL. A comparison of CD10 to pCEA, MOC-31, and hepatocyte for the distinction of malignant tumors in the liver. Mod. Pathol. 2002 15 1279 1287.
7. Lau SK, Prakash S, Geller SA et al. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum. Pathol. 2002 33 1175 1181.
8. Iwaya K, Ogawa H, Izumi M et al. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome. Virchows Arch. 2002 440 589 593.
9. Ogawa H, Iwaya K, Izumi M et al. Expression of CD10 by stromal cells during colorectal tumor development. Hum. Pathol. 2002 33 806 811.
10. Iezzi G, Piattelli A, Rubini C et al. CD10 expression in stromal cells of ameloblastoma variants. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2008 105 206 209.
11. Piattelli A, Fioroni M, Iezzi G et al. CD10 expression in stromal cells of oral cavity squamous cell carcinoma: a clinic and pathologic correlation. Oral Dis. 2006 12 301 304.
12. Makretsov NA, Hayes M, Carter BA et al. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod. Pathol. 2007 20 84 89.
13. Bilalovic N, Sandstad B, Golouh R et al. CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression. Mod. Pathol. 2004 17 1251 1258.
14. Braham H, Trimeche M, Ziadi S et al. CD10 expression by fusiform stromal cells in nasopharyngeal carcinoma correlates with tumor progression. Virchows Arch. 2006 449 220 224.
15. Huang WB, Zhou XJ, Chen JY et al. CD10-positive stromal cells in gastric carcinoma: correlation with invasion and metastasis. Jpn. J. Clin. Oncol. 2005 35 245 250.
16. Dawson LA, Maitland NJ, Turner AJ et al. Stromal-epithelial interactions influence prostate cancer cell invasion by altering the balance of metallopeptidase expression. Br. J. Cancer 2004 90 1577 1582.
17. Wittekind C, Fischer HP, Ponchon T. Intrahepatic cholangiocarcinoma. In Nakanuma Y, Sripa B, Vatanasapt V et al. eds. World Health Organization classification of tumours: pathology and genetics of tumours of the digestive system. Lyon, France : IARC Press, 2000 173 180.
18. Liver Cancer Study Group. The general rules for the clinical and pathological study of primary liver cancer, 4th edn. Tokyo : Kanahara Publication, 2000.
19. Altaee MY, Johnson PJ, Farrant JM et al. Etiologic and clinical characteristics of peripheral and hilar cholangiocarcinoma. Cancer 1991 68 2051 2055.
20. Nakajima T, Kondo Y, Miyazaki M et al. A histopathologic study of 102 cases of intrahepatic cholangiocarcinoma: histologic classification and modes of spreading. Hum. Pathol. 1988 19 1228 1234.
21. Shimonishi T, Sasaki M, Nakanuma Y. Precancerous lesions of intrahepatic cholangiocarcinoma. J. Hepatobiliary Pancreat. Surg. 2000 7 542 550.
22. Zen Y, Adsay NV, Bardadin K et al. Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod. Pathol. 2007 20 701 709.
23. Aishima S, Kuroda Y, Nishihara Y et al. Proposal of progression model for intrahepatic cholangiocarcinoma: clinicopathologic differences between hilar type and peripheral type. Am. J. Surg. Pathol. 2007 31 1059 1067.
24. Nakamura T, Matsumoto K, Kiritoshi A et al. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res. 1997 57 3305 3313.
25. Camps JL, Chang SM, Hsu TC et al. Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc. Natl Acad. Sci. USA 1990 87 75 79.
26. Aishima S, Matsuura S, Terashi T et al. Aberrant expression of laminin gamma 2 chain and its prognostic significance in intrahepatic cholangiocarcinoma according to growth morphology. Mod. Pathol. 2004 17 938 945.
27. Nakanuma Y, Harada K, Ishikawa A et al. Anatomic and molecular pathology of intrahepatic cholangiocarcinoma. J. Hepatobiliary Pancreat. Surg. 2003 10 265 281.
28. Itatsu K, Zen Y, Yamaguchi J et al. Expression of matrix metalloproteinase 7 is an unfavorable postoperative prognostic factor in cholangiocarcinoma of the perihilar, hilar, and extrahepatic bile ducts. Hum. Pathol. 2008 39 710 719.
29. Jo Chae K, Rha SY, Oh BK et al. Expression of matrix metalloproteinase-2 and -9 and tissue inhibitor of metalloproteinase-1 and -2 in intraductal and nonintraductal growth type of cholangiocarcinoma. Am. J. Gastroenterol. 2004 99 68 75.
30. Akahane T, Ishii M, Ohtani H et al. Stromal expression of urokinase-type plasminogen activator receptor (uPAR) is associated with invasive growth in primary liver cancer. Liver 1998 18 414 419.
31. Basset P, Wolf C, Rouyer N et al. Stromelysin-3 in stromal tissue as a control factor in breast cancer behavior. Cancer 1994 74 1045 1049.
32. Talvensaari-Mattila A, Paakko P, Hoyhtya M et al. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 1998 83 1153 1162.